– Notification of publication of 2025 Interim Report (the "Current Corporate Communications") on the Company's website Brii Biosciences Limited 騰盛博藥生物科技有限公司 (A company incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號: 2137) NOTIFICATION LETTER 通知信函 Dear Registered Shareholder, September 19, 2025 Brii Biosciences Limited (the "Company") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at http: ...

Brii Biosciences Limited 騰盛博藥生物科技有限公司 ( 於開曼群島註冊成立的有限公司 ) 股份代號 : 2137 2025 中期報告 目 錄 | | 頁次 | | --- | --- | | 公司簡介 | 2 | | 公司資料 | 3 | | 管理層討論及分析 | 5 | | 企業管治及其他資料 | 19 | | 簡明合併財務報表審閱報告 | 44 | | 簡明合併損益及其他綜合收益表 | 45 | | 簡明合併財務狀況表 | 47 | | 簡明合併權益變動表 | 49 | | 簡明合併現金流量表 | 50 | | 簡明合併財務報表附註 | 51 | | 釋義 | 67 | 公司簡介 騰盛博藥生物科技有限公司是一家領先的生物技術公司，致力於為醫療需求高度未滿足的領域，特別是感染病， 開發創新療法。於2025年前六個月，本公司推進其核心乙肝功能性治癒項目，同時繼續通過外部合作和內部發現 來創造價值。隨著三項互補的2b期臨床研究現已全部完成受試者招募，本公司已為實現其研發慢性HBV有效功能 性治癒方法的目標奠定了重要基礎。 ENSURE、ENRICH及ENHANCE研究構成本公司HBV臨床 ...

Core Viewpoint - Tengsheng Bo Pharmaceutical-B (02137) announced the issuance of a total of 159,900 shares due to the grant of restricted stock units from September 1 to September 17, 2025 [1] Summary by Relevant Categories - **Company Actions** - The company will issue a total of 159,900 shares as part of the restricted stock units granted [1] - **Timeline** - The issuance will occur between September 1 and September 17, 2025 [1]

Group 1 - The company, Tengsheng Bo Pharmaceutical-B (02137), announced the issuance of a total of 159,900 shares due to the allocation of restricted stock units from September 1 to September 17, 2025 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 騰盛博藥生物科技有限公司 呈交日期： 2025年9月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 2). 就根據股份計劃授予參與人（發行人的董事除外）的股份獎勵或期權 | | 86,430 0.012 % HKD 0 | | --- | --- | --- | | 而發行新股或轉讓庫存股份 - 涉及新股 | | | | 根據於2021年6月22日採納的本公司首次公開發售後股份獎勵計劃， | | | | 歸屬授出的受限制股份單位而發行及配發予本公司僱員之股份。 | | | | 變動日期 2025年9月2日 | | | | 3). 就根據股份計劃授予參與人（發行人的董事除外）的股份獎勵或期權 | | 49,550 0.0069 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 騰盛博藥生物科技有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 FF301 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02137 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,200,000,000 | USD | | 0.000005 | USD | | 6,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,200,000,000 | USD | | 0.000005 | USD ...

Announcement Background and Purpose Brii Biosciences Limited issues a supplemental announcement to provide additional details on the use of net proceeds from its global offering in the 2024 annual report, specifically regarding unutilized funds carried forward to January 1, 2024 - This announcement supplements the 2024 annual report, focusing on the use of net proceeds from the global offering[2](index=2&type=chunk) - It highlights the specific amount of **unutilized net proceeds** as of December 31, 2023, carried forward to January 1, 2024[2](index=2&type=chunk) [Details on Use of Net Proceeds from Global Offering](index=2&type=section&id=%E5%85%A8%E7%90%83%E7%99%BC%E5%94%AE%E6%89%80%E5%BE%97%E6%AC%BE%E9%A0%AD%E6%B7%A8%E9%A1%8D%E7%94%A8%E9%80%94%E8%A9%B3%E6%83%85) This section details the original and revised uses of the company's global offering net proceeds, utilized amounts as of December 31, 2024, and unutilized funds carried forward from December 31, 2023, to January 1, 2024, covering various R&D projects and working capital - As of December 31, 2024, a total of **HKD 25.256 million** of net proceeds from the global offering has been utilized (**HKD 9.941 million** from Group 1 allocation and **HKD 15.315 million** from Group 2 allocation)[3](index=3&type=chunk)[4](index=4&type=chunk) - As of December 31, 2024, **HKD 1.760 million** remains unutilized, primarily allocated to Group 1 R&D projects and working capital[3](index=3&type=chunk) [Unutilized Net Proceeds as of December 31, 2023, Carried Forward to January 1, 2024](index=2&type=section&id=2.1%20%E6%88%AA%E8%87%B32023%E5%B9%B412%E6%9C%8831%E6%97%A5%E6%9C%AA%E5%8B%95%E7%94%A8%E6%89%80%E5%BE%97%E6%AC%BE%E9%A0%AD%E6%B7%A8%E9%A1%8D%E7%B5%90%E8%BD%89%E8%87%B32024%E5%B9%B41%E6%9C%881%E6%97%A5) As of December 31, 2023, **HKD 14.666 million** of the company's global offering net proceeds remained unutilized and was carried forward to January 1, 2024, primarily for R&D projects like BRII-179, BRII-877, and working capital Unutilized Net Proceeds as of December 31, 2023, Carried Forward to January 1, 2024 (Million HKD) | Project | Original Proposed Use (Million HKD) | Revised Proposed Use (Million HKD) | Unutilized Net Proceeds (Million HKD) | Percentage of Original Total Net Proceeds (%) | | :------------- | :------------------------------- | :------------------------------- | :------------------------------- | :------------------------- | | BRII-179 | 11.959 | 11.959 | 7.848 | 46% | | BRII-732 | 1.307 | 1.307 | 1.400 | 5% | | BRII-835 | 0.261 | 0.261 | 1.307 | 5% | | BRII-877 | 14.666 | 14.666 | 5.141 | 56% | | BRII-753 | 1.400 | 1.400 | 1.400 | 6% | | Other R&D Projects | 1.517 | 1.517 | 1.517 | 32% | | Working Capital and Other General Corporate Purposes | 8.373 | 8.373 | 11.959 | 1% | | **Total** | **26.138** | **26.138** | **14.666** | **100%** | [Overview of Net Proceeds Utilization as of December 31, 2024](index=2&type=section&id=2.2%20%E6%88%AA%E8%87%B32024%E5%B9%B412%E6%9C%8831%E6%97%A5%E6%89%80%E5%BE%97%E6%AC%BE%E9%A0%AD%E6%B7%A8%E9%A1%8D%E7%94%A8%E9%80%94%E6%A6%82%E8%A7%88) As of December 31, 2024, a total of **HKD 25.256 million** from the global offering net proceeds has been utilized (**HKD 9.941 million** from Group 1 and **HKD 15.315 million** from Group 2), with **HKD 1.760 million** remaining unutilized, primarily in Group 1 R&D projects and working capital [Utilization of Group 1 Allocated Funds](index=2&type=section&id=2.2.1%20%E7%AC%AC%E4%B8%80%E7%BB%84%E5%88%86%E9%85%8D%E7%9A%84%E8%B5%84%E9%87%91%E4%BD%BF%E7%94%A8%E6%83%85%E5%86%B5) Of the **HKD 26.138 million** net proceeds from the global offering allocated to Group 1, **HKD 9.941 million** was utilized as of December 31, 2024, primarily for R&D projects like BRII-179, BRII-877, and working capital, with **HKD 1.760 million** remaining unutilized Utilization of Group 1 Allocated Funds as of December 31, 2024 (Million HKD) | Project/Purpose | Original Proposed Use (Million HKD) | Revised Proposed Use (Million HKD) | Funds Utilized (Million HKD) | Unutilized Net Proceeds as of 2024-12-31 (Million HKD) | | :--------------------- | :------------------------------- | :------------------------------- | :------------------------------- | :----------------------------------------------------------------- | | BRII-179 | 11.959 | 11.959 | 6.818 | 1.555 | | BRII-732 | 1.307 | 1.307 | 1.517 | 1.307 | | BRII-835 | 0.261 | 0.261 | 0.243 | 0.261 | | BRII-877 | 14.666 | 14.666 | 3.123 | 1.825 | | BRII-753 | 1.400 | 1.400 | 1.825 | 0.053 | | Other R&D Projects | 1.517 | 1.517 | 4.948 | 3.380 | | Working Capital and Other General Corporate Purposes | 8.373 | 8.373 | 0.296 | 0.261 | | **Total** | **26.138** | **26.138** | **9.941** | **1.760** | [Utilization of Group 2 Allocated Funds](index=3&type=section&id=2.2.2%20%E7%AC%AC%E4%BA%8C%E7%BB%84%E5%88%86%E9%85%8D%E7%9A%84%E8%B5%84%E9%87%91%E4%BD%BF%E7%94%A8%E6%83%85%E5%86%B5) The **HKD 15.315 million** net proceeds from the global offering allocated to Group 2 were fully utilized as of December 31, 2024, primarily for R&D projects like BRII-297, BRII-636, and working capital, with no unutilized balance Utilization of Group 2 Allocated Funds as of December 31, 2024 (Million HKD) | Project/Purpose | Original Proposed Use (Million HKD) | Revised Proposed Use (Million HKD) | Funds Utilized (Million HKD) | Unutilized Net Proceeds as of 2024-12-31 (Million HKD) | | :--------------------- | :------------------------------- | :------------------------------- | :------------------------------- | :----------------------------------------------------------------- | | BRII-297 | 0.675 | 0.675 | 0.675 | 0 | | BRII-636 | 0.590 | 0.590 | 0.590 | 0 | | BRII-672 | 0.085 | 0.085 | 0.085 | 0 | | BRII-296 | 2.746 | 2.746 | 2.746 | 0 | | BRII-693 | 3.920 | 3.920 | 3.920 | 0 | | Other R&D Projects | 2.614 | 2.614 | 2.614 | 0 | | Working Capital and Other General Corporate Purposes | 26.138 | 26.138 | 26.138 | 0 | | **Total** | **15.315** | **15.315** | **15.315** | **0** | [Other Information and Board Statement](index=4&type=section&id=%E5%85%B6%E4%BB%96%E4%BF%A1%E6%81%AF%E4%B8%8E%E8%91%A3%E4%BA%8B%E4%BC%9A%E5%A3%B0%E6%98%8E) The additional information disclosed in this supplemental announcement does not affect other content in the 2024 annual report, with all other information remaining unchanged, and includes details on the company's board members - The additional information in this supplemental announcement does not affect other information in the 2024 annual report[5](index=5&type=chunk) - Board members include Executive Directors Dr Zhi Hong and Dr Li Ankang, along with several Independent Non-executive Directors[6](index=6&type=chunk)

Group 1 - The company, Tengsheng Bo Pharmaceutical-B (02137), announced the issuance and allocation of 130,800 shares to employees as part of its restricted share unit plan adopted on June 22, 2021 [1]

Group 1 - The company, Tengsheng Bo Pharmaceutical-B (02137), announced the issuance and allocation of 130,800 shares to employees as part of its restricted share unit plan adopted on June 22, 2021 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | | 02137 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 事件 | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | 每股發行/出售價 (註4) | | 已發行股份總數 | | | | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | | | | 於下列日期開始時的結存(註1) | | 2025年7月31日 | | 719,377,383 | | 12,723,500 ...